Natural and Expanded CD4+CD25+ Regulatory T Cells in Bone Marrow Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 1 SUPPL, 2011, Pages

  Colonna, Lucrezia ^a   Sega, Emanuela I ^a   Negrin, Robert S ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BIOLUMINESCENCE; BONE MARROW TRANSPLANTATION; CD4+ CD25+ T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; REGULATORY T LYMPHOCYTE;

EID: 78650666734     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.10.020     Document Type: Article

References (57)

1. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
2. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
3. Chen W., Jin W., Hardegen N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-1886.
4. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
5. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010, 11:7-13.
6. Bennett C.L., Christie J., Ramsdell F., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
7. Wildin R.S., Ramsdell F., Peake J., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001, 27:18-20.
8. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3:199-210.
9. Nagahama K., Nishimura E., Sakaguchi S. Induction of tolerance by adoptive transfer of Treg cells. Methods Mol Biol 2007, 380:431-442.
10. Dai Z., Li Q., Wang Y., et al. CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J Clin Invest 2004, 113:310-317.
11. Edinger M., Hoffmann P., Ermann J., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9:1144-1150.
12. Nguyen V.H., Shashidhar S., Chang D.S., et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood 2008, 111:945-953.
13. Hoffmann P., Ermann J., Edinger M., Fathman C.G., Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002, 196:389-399.
14. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
15. Cohen J.L., Trenado A., Vasey D., Klatzmann D., Salomon B.L. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med 2002, 196:401-406.
16. Trenado A., Charlotte F., Fisson S., et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003, 112:1688-1696.
17. Jones S.C., Murphy G.F., Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant 2003, 9:243-256.
18. Negrin R.S., Contag C.H. In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease. Nat Rev Immunol 2006, 6:484-490.
19. Nguyen V.H., Zeiser R., Dasilva D.L., et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 2007, 109:2649-2656.
20. Beilhack A., Schulz S., Baker J., et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 2005, 106:1113-1122.
21. Ermann J., Hoffmann P., Edinger M., et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005, 105:2220-2226.
22. Taylor P.A., Panoskaltsis-Mortari A., Swedin J.M., et al. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004, 104:3804-3812.
23. Wysocki C.A., Jiang Q., Panoskaltsis-Mortari A., et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood 2005, 106:3300-3307.
24. Huang C.T., Workman C.J., Flies D., et al. Role of LAG-3 in regulatory T cells. Immunity 2004, 21:503-513.
25. Liang B., Workman C., Lee J., et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 2008, 180:5916-5926.
26. Sarris M., Andersen K.G., Randow F., Mayr L., Betz A.G. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008, 28:402-413.
27. Zeiser R., Nguyen V.H., Hou J.Z., et al. Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood 2007, 109:2225-2233.
28. Fernandez I., Zeiser R., Karsunky H., et al. CD101 surface expression discriminates potency among murine FoxP3+ regulatory T cells. J Immunol 2007, 179:2808-2814.
29. Malek T.R., Bayer A.L. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004, 4:665-674.
30. Nelson B.H. IL-2, regulatory T cells, and tolerance. J Immunol 2004, 172:3983-3988.
31. Thornton A.M., Donovan E.E., Piccirillo C.A., Shevach E.M. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004, 172:6519-6523.
32. Salomon B., Lenschow D.J., Rhee L., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12:431-440.
33. Tang Q., Henriksen K.J., Boden E.K., et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003, 171:3348-3352.
34. Hoffmann P., Eder R., Kunz-Schughart L.A., Andreesen R., Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 2004, 104:895-903.
35. Earle K.E., Tang Q., Zhou X., et al. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin Immunol 2005, 115:3-9.
36. Kreijveld E., Koenen H.J., Hilbrands L.B., Joosten I. Ex vivo expansion of human CD4+ CD25high regulatory T cells from transplant recipients permits functional analysis of small blood samples. J Immunol Methods 2006, 314:103-113.
37. Kasow K.A., Chen X., Knowles J., Wichlan D., Handgretinger R., Riberdy J.M. Human CD4+CD25+ regulatory T cells share equally complex and comparable repertoires with CD4+CD25- counterparts. J Immunol 2004, 172:6123-6128.
38. Godfrey W.R., Ge Y.G., Spoden D.J., et al. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 2004, 104:453-461.
39. Cao T., Soto A., Zhou W., et al. Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD). Cell Immunol 2009, 258:65-71.
40. Levings M.K., Sangregorio R., Roncarolo M.G. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001, 193:1295-1302.
41. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105:4743-4748.
42. Basu S., Golovina T., Mikheeva T., June C.H., Riley J.L. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008, 180:5794-5798.
43. Strauss L., Czystowska M., Szajnik M., Mandapathil M., Whiteside T.L. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One 2009, 4:e5994.
44. Fu S., Yopp A.C., Mao X., et al. CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant 2004, 4:65-78.
45. Hoffmann P., Eder R., Boeld T.J., et al. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006, 108:4260-4267.
46. Tran D.Q., Andersson J., Hardwick D., Bebris L., Illei G.G., Shevach E.M. Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood 2009, 113:5125-5133.
47. Jiang S., Camara N., Lombardi G., Lechler R.I. Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo. Blood 2003, 102:2180-2186.
48. Jiang S., Tsang J., Game D.S., Stevenson S., Lombardi G., Lechler R.I. Generation and expansion of human CD4+ CD25+ regulatory T cells with indirect allospecificity: Potential reagents to promote donor-specific transplantation tolerance. Transplantation 2006, 82:1738-1743.
49. Masteller E.L., Warner M.R., Tang Q., Tarbell K.V., McDevitt H., Bluestone J.A. Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol 2005, 175:3053-3059.
50. Golshayan D., Jiang S., Tsang J., Garin M.I., Mottet C., Lechler R.I. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 2007, 109:827-835.
51. Peters J.H., Hilbrands L.B., Koenen H.J., Joosten I. Ex vivo generation of human alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy. PLoS One 2008, 3:e2233.
52. Trenado A., Sudres M., Tang Q., et al. Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol 2006, 176:1266-1273.
53. Floess S., Freyer J., Siewert C., et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007, 5:e38.
54. Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 116:129-139.
55. Brunstein C., Hippen K.L., McKenna D.H., et al. Adoptive transfer of umbilical cord blood (UCB)-derived regulatory T cells (Tregs) to recipients of nonmyeloablative unrelated double UCB transplantation. ASH Annu Meet Abstr 2009, 114:513.
56. Di Ianni M., Falzetti F., Carotti A., et al. Adoptive Immunotherapy with Tregs prevents GvHD and favours immune reconstitution after HLA haploidentical transplants for hematological malignancies. ASH Annu Meet Abstr 2009, 114:4.
57. Zorn E., Mohseni M., Kim H., et al. Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:382-388.